Reed-Sternberg cells in Hodgkin Lymphomas Silencing of the p18INK4c gene by promoter hypermethylation in the

[1]  V. Diehl,et al.  Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. , 2003, Blood.

[2]  A. Sánchez-Aguilera,et al.  Cell cycle deregulation in B-cell lymphomas. , 2003, Blood.

[3]  V. Godfrey,et al.  Haploinsufficiency of p18INK4c Sensitizes Mice to Carcinogen-Induced Tumorigenesis , 2003, Molecular and Cellular Biology.

[4]  S. Pileri,et al.  High‐throughput tissue microarray analysis of G1‐cyclin alterations in classical Hodgkin's lymphoma indicates overexpression of cyclin E1 , 2003, The Journal of pathology.

[5]  Lydia Sánchez,et al.  Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. , 2003, Blood.

[6]  J. Teruya-Feldstein,et al.  Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. , 2002, Human pathology.

[7]  J. Benítez,et al.  Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's and CD30-Positive non-Hodgkin's lymphomas. , 2002, The American journal of pathology.

[8]  A. Blais,et al.  Regulation of the Human Cyclin-dependent Kinase Inhibitor p18 INK4c by the Transcription Factors E2F1 and Sp1* , 2002, The Journal of Biological Chemistry.

[9]  S. Ely,et al.  CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells. , 2002, Immunity.

[10]  S. Hamilton-Dutoit,et al.  Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma , 2002, Oncogene.

[11]  Susan J Clark,et al.  Methylation sequencing from limiting DNA: embryonic, fixed, and microdissected cells. , 2002, Methods.

[12]  H. Stein,et al.  Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. , 2002, Blood.

[13]  D. Hossfeld.  E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .

[14]  D. Franklin,et al.  An Important Role of CDK Inhibitor p18INK4c in Modulating Antigen Receptor-Mediated T Cell Proliferation1 , 2001, The Journal of Immunology.

[15]  B. Dörken,et al.  Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. , 2001, Blood.

[16]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[17]  M. Barbacid,et al.  Limited overlapping roles of P15INK4b and P18INK4c cell cycle inhibitors in proliferation and tumorigenesis , 2000, The EMBO journal.

[18]  J. Benítez,et al.  Hypermethylation of P16ink4a and P15ink4b genes as a marker of disease in the follow‐up of non‐Hodgkin's lymphomas , 2000, British journal of haematology.

[19]  M. Piris,et al.  Loss of p16 protein expression associated with methylation of the p16INK4A gene is a frequent finding in Hodgkin's disease. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[20]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[21]  J. Armitage,et al.  A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.

[22]  V. Godfrey,et al.  CDK inhibitors p18 INK4c and p27 Kip1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis , 1998 .

[23]  J. Benítez,et al.  Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. , 1998, The American journal of pathology.

[24]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[25]  A. Blais,et al.  Structure of the gene encoding the human cyclin-dependent kinase inhibitor p18 and mutational analysis in breast cancer. , 1998, Biochemical and biophysical research communications.

[26]  H. Drexler.  Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia–lymphoma cells , 1998, Leukemia.

[27]  J. Herman,et al.  Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. , 1997, Cancer research.

[28]  Carl W. Miller,et al.  Analysis of the p16INK4A, p15INK4B and p18INK4C genes in multiple myeloma , 1997, British journal of haematology.

[29]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Iolascon,et al.  Homozygous deletions of cyclin-dependent kinase inhibitor genes, p16(INK4A) and p18, in childhood T cell lineage acute lymphoblastic leukemias. , 1996, Leukemia.

[31]  R. Siebert,et al.  Analysis of the novel cyclin-dependent kinase 4 and 6 inhibitor gene p18 in lymphoma and leukemia cell lines. , 1996, Leukemia research.

[32]  M. Raffeld,et al.  Absence of p18 mutations or deletions in lymphoid malignancies. , 1996, Leukemia.

[33]  Kathleen R. Cho,et al.  Frequency of homozygous deletion at p16/CDKN2 in primary human tumours , 1995, Nature Genetics.

[34]  M. Raffeld,et al.  Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas. , 1995, Cancer research.

[35]  M. Yuille,et al.  Deletions and rearrangement of CDKN2 in lymphoid malignancy. , 1995, Blood.

[36]  C. O'keefe,et al.  Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. , 1994, Genes & development.

[37]  L. E. McDonald,et al.  A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[38]  W. Kuehl,et al.  Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis , 2002, Leukemia.

[39]  K. Rajewsky,et al.  Clonality and germinal centre B-cell derivation of Hodgkin/Reed-Sternberg cells in Hodgkin's disease. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  M. Williams,et al.  Analysis of the cyclin-dependent kinase inhibitors p18 and p19 in mantle-cell lymphoma and chronic lymphocytic leukemia. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  D. Franklin,et al.  Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6. , 1997, Immunity.